Aniracetam Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: AMPA modulation and cognitive function

Nootropic Compounds compound PowderCapsule verified

Also known as: Draganon, Sarpul

Quick Facts

Reference Sizes
750 mg capsules, 10 g powder, 25 g powder
Storage
Store tightly sealed in cool dry conditions and follow the product label
Solubility
Fat-soluble; poorly water-soluble; dissolve in oil or take with dietary fat

Catalog Description

Aniracetam is a fat-soluble racetam studied for AMPA receptor positive allosteric modulation, acetylcholine release enhancement, and mGluR1/5 modulation, metabolized to anisoyl-GABA and related compounds. It belongs to the first structural class of racetams (with piracetam, oxiracetam, and phenylpiracetam) explored as cognitive-enhancement add-ons; like other racetams, its precise mechanism remains only partially characterized and clinical evidence quality is mixed/limited.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life
Approximately 0.5 hours for the parent compound after a single 400 mg oral dose; active metabolites persist longer
Onset
Peak parent-compound concentration occurred at about 0.4 hours in a single-dose human pharmacokinetic study; clinical outcomes were assessed over months
Administration Routes (Research)
Oral

Reported Research Effects

Reported Research Side Effects

Data source: Racetam-class pharmacology review literature

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established
Oral Human study only

1500 mg/day in divided doses

Frequency / timing
Daily
Duration / setting
6 months
Technique
Oral
Evidence
Human study protocol

Context: double-blind multicenter clinical studies in elderly cognitive-impairment populations

Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.

Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Notes

Typically sold as 750 mg capsules.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/19025058/
Clinical Experience with Aniracetam in the Treatment of Senile Dementia of the Alzheimer's Type and Related Disorders — Clinical Drug Investigation
https://link.springer.com/article/10.1007/BF03258430
Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors — PubMed Central (NIH)
https://pmc.ncbi.nlm.nih.gov/articles/PMC6725607/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top